EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein

Tomaz B Manzoni iD, Jonna B Westover iD, Kendall A Lundgreen, Philip D Hicks iD, Raegan J Petch iD, Jordan T Ort, Drew Weissman, Steven H Y Fan, Scott E Hensley, Norbert Pardi iD, Brian B Gowen iD, Paul Bates iD

Viruses · 2025

DOI: 10.3390/v17081095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Tomaz B Manzoni und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Hauptthemen laut MEDLINE: Viral Vaccines, Phlebovirus, Glycoproteins, Severe Fever with Thrombocytopenia Syndrome. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Severe fever with thrombocytopenia syndrome virus (SFTSV) is a highly pathogenic bunyavirus with a high case-fatality ratio for which there is no approved vaccine. Studies have assessed different vaccine technologies. However, few studies have yet assessed the immunogenicity of heterologous prime-boost regimens.

Methods

Here, we compare a lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA-based vaccine encoding the SFTSV glycoproteins, Gn and Gc, to our recently described recombinant VSV SFTSV (rVSV-SFTSV) vaccine in single dose, homologous, and heterologous prime-boost regimens in mice.

Results

We show that all regimens protect from pathogenic SFTSV challenge and elicit strong long-lasting antibody responses. Furthermore, strong cellular immunity is elicited by mRNA-LNP immunizations and by heterologous immunization with an rVSV-SFTSV prime and mRNA-LNP boost. Cellular responses robustly polarized towards a type 1 response, characterized by high levels of IFNγ, TNFα, and IL-2. Immunization with mRNA led to a mixed type 1/type 2 immune response, as determined by antibody isotypes IgG1 and IgG2c. We found that homologous immunization leads to stronger antibody responses while heterologous immunization drives a slightly stronger cellular response.

Conclusions

Taken together, the vaccine platforms described here represent strong vaccine candidates for further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Viral VaccinesPhlebovirusGlycoproteinsSevere Fever with Thrombocytopenia SyndromeAnimalsMiceAntibodies, ViralRNA, MessengerVaccinationFemaleVaccines, SyntheticImmunity, CellularMice, Inbred BALB CAntibodies, NeutralizingImmunoglobulin GmRNA VaccinesNanoparticles

Stichwörter der Autor:innen

Dabie bandavirusimmunogenicitymRNArVSVsevere fever with thrombocytopenia syndrome virusvaccinevesicular stomatitis virus

Substanzen

Viral VaccinesAntibodies, ViralRNA, MessengerGlycoproteinsVaccines, SyntheticAntibodies, NeutralizingImmunoglobulin GmRNA Vaccines

Autor:innen und Institutionen

  • Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT 84322, USA.
  • Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Acuitas Therapeutics, Vancouver, BC V6T 1Z3, Canada.

ORCID-Profile: Tomaz B Manzoni, Jonna B Westover, Philip D Hicks, Raegan J Petch, Norbert Pardi, Brian B Gowen, Paul Bates

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health (NIH)

Zitieren

APA

Manzoni, T. B., Westover, J. B., Lundgreen, K. A., Hicks, P. D., Petch, R. J., Ort, J. T., Weissman, D., Fan, S. H. Y., Hensley, S. E., Pardi, N., Gowen, B. B., & Bates, P. (2025). Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein. Viruses. https://doi.org/10.3390/v17081095

Vancouver

Manzoni TB, Westover JB, Lundgreen KA, Hicks PD, Petch RJ, Ort JT, et al. Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein. Viruses. 2025. doi:10.3390/v17081095

BibTeX
@article{Manzoni2025,
  author = {Manzoni, Tomaz B and Westover, Jonna B and Lundgreen, Kendall A and Hicks, Philip D and Petch, Raegan J and Ort, Jordan T and Weissman, Drew and Fan, Steven H Y and Hensley, Scott E and Pardi, Norbert and Gowen, Brian B and Bates, Paul},
  title = {Homologous and Heterologous Vaccination Regimens with mRNA and rVSV Platforms Induce Potent Immune Responses Against SFTSV Glycoprotein},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17081095}
}
Kostenlos starten →